Steven J Burakoff, MD
- PROFESSOR | Oncological Sciences
- PROFESSOR | Medicine, Hematology and Medical Oncology
- PROFESSOR | Pediatrics, Hematology/Oncology
Research Topic:T Cells
Steven J. Burakoff, M.D., is currently the Lillian and Henry Stratton Professor of Medicine and served as Director of The Tisch Cancer Institute at the Icahn School of Medicine from 2007-2017. He is currently, Dean for Cancer Innovation and Chief, Pediatric Oncology at the Icahn School of Medicine. Prior to his appointment in 2007 to the Icahn School of Medicine, Dr. Burakoff was the Laura and Isaac Perlmutter Professor at New York University School of Medicine, the Director of the New York University Cancer Institute, and the Director of the Skirball Institute of Biomolecular Medicine.
Prior to joining the New York University School of Medicine, in 2000, he was Chair of Pediatric Oncology at the Dana-Farber Cancer Institute and the Margaret M. Dyson Professor of Pediatrics at the Harvard Medical School, and also received an Honorary Master’s of Science Degree from Harvard University. He was the recipient of the first Harvard Medical School Excellence in Mentoring Award. He was also the Ted Williams Senior Investigator at the Dana-Farber Cancer Institute, and served as a member of the Board of Trustees of the Dana-Farber Cancer Institute. Dr. Burakoff serves as a member of the External Advisory Committee of the Cold Spring Harbor Laboratory Cancer Center, University of Florida Cancer Center, and the Stony Brook Cancer Center. He is also on the Board of Directors of the Damon Runyon Cancer Foundation and he is on the Joint Scientific Advisory Board for Stand Up to Cancer.
Dr. Burakoff holds memberships in many professional societies and organizations, including: Alpha Omega Alpha, the American Society of Clinical Investigation, and the Association of American Physicians, and the American Association of Immunologist where he served as Secretary-Treasurer. He has been an Editor and Associate Editor for numerous journals and author of more than 300 publications in peer-reviewed journals. In 2009, Dr. Burakoff received the American Association of Immunologists Lifetime Achievement Award.
American Board of Internal Medicine
Multi-Disciplinary Training AreasCancer Biology [CAB], Immunology [IMM]
MD, Albany Medical College
MA, Queens College
MA (hon), Harvard University
Harvard Medical School
New York Hospital-Cornell Medical Center
Internship, General Medicine, Cornell Medical Center
Residency, General Medicine, Cornell Medical Center
Fellowship, Immunology, Rockefeller University
Lifetime Achievement Award
Lynne Cohen Foundation Awardee
Distinguished Alumnus 2003
Theobold Smith Alumni Lecture
ISI Highly Cited Researcher (1980-2000)
Laura and Isaac Perlmutter Professor
Margaret M. Dyson Professor of Pediatrics
Ted Williams Senior Investigator
Association of American Physicians
Horizons in Biomedical Research Lecture
David A. Talmadge Lecture
Major Research Interests:
1. Cellular and molecular immunology;
2. T cell activation and signal transduction;
3. Transplantation immunology.
Jin YJ, Cai CY, Zhang X, Zhang HT, Burakoff SJ. Lysine144, a Ubiquitin Attachment Site in HIV-1 Nef, Is Required for Nef-mediated CD4 Downregulation. J Immunol 2008;.
Sawasdikosol S, Pyarajan S, Alzabin S, Matejovic G, Burakoff SJ. Prostaglandin E2 activates HPK1 activity via a PKA-dependent pathway. J Biol Chem 2007 Nov; 282: 34693-34699.
Mathews JP, Taylor BS, Bader GD, Pyarajan S, Antoniotti M, Chinnaiyan AM, Sander C, Burakoff SJ, Mishra B. From bytes to bedside: data integration and computational biologyfor translational cancer research. PLoS Comput Biol 2007 Feb 23; 3(2): e12.
Fragoso R, Pyarajan S, Irie HY, Burakoff SJ. CD8/Lck transgene is able to drive thymocyte differentiation. J. Immun 2006 Feb 15; 176(4): 2669.
Jin JJ, Yi Cai C, Zhang X, Zhang HT, Hirst JA, Burakoff SJ. HIV Nef-mediated CD4 down-regulation is adaptor protein complex 2 dependent. J. Immun 2006 Feb 15; 176(4): 2669.
Zambricki E, Shigeoka A, Kishimoto H, Sprent J, Burakoff S, Carpenter C, Milford E, McKay D. Signaling T cell survival and death by IL-2 and IL-15. Am J Transplant 2005; 11: 2623-2631.
Su MW, Pyarajan S, Chang JH, Yu CL, Jin YJ, Stierhof YD, Walden P, Burakoff SJ. Fratricide of CD8+ cytotoxic T Lymphocytes is dependent on cellular activation and perforin-mediated killing. Eur J Immunol 2004; 34: 2459-2470.
Frazer-Abel AA, Baksh S, Fosmire SP, Willis D, Pierce AM, Meylemans H, Linthicum DS, Burakoff SJ, Coons T, Bellgrau D. Nicotine activates NFATc2 and prevents cell cycle entry in T cells. J Pharmacol Exp Ther 2004; 311: 758-769.
Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwiz D, Boyd A, Kupper TS, Burakoff SJ. Increasing T cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Biol Blood Marrow Transplant 2004; 10: 448-460.
Friedman JS, Lopez MF, Fleming MD, Rivera A, Martin FM, Welsh ML, Boyd AS, Doctrow SR, Burakoff SJ. SOD2 Deficiently anemia: protein oxidation and altered protein expression reveal targets of damage, stress response and anti -oxidant responsiveness. Blood 2004; 104: 2565-2573.